Last reviewed · How we verify
NCT05795374: NUFAGI
Nutritional and Functional Assessment of Patients Undergoing Surgery Due to Gastrointestinal Cancer (NUFAGI).
trial in Gastrointestinal Cancer in 300 participants. Completed in 20 December 2023.
20 December 2023
Quick facts
| Lead sponsor | Maximos Frountzas |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 March 2022 |
| Primary completion | 20 December 2023 |
| Estimated completion | 20 December 2023 |
| Sites | 1 location across Greece |
Conditions studied
- Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →
Sponsor
Maximos Frountzas
Who can join
Adults 18 to 99, any sex, with Gastrointestinal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Several patients that suffer from gastrointestinal (GI) cancer are characterized by malnutrition and impairment of their functional status. The aim of the present study is to evaluate the nutritional condition of patients undergoing surgery due to GI cancer and compare it with their functional status. All consecutive patients with esophageal, gastric, colorectal, hepatocellular, pancreatic and biliary cancer, that underwent a surgical operation will be included. Demographic characteristics, nutritional assessment and anthropometric measurements of the patients will be recorded.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Predictive Role of Preoperative Malnutrition Assessment in Postoperative Outcomes of Patients Undergoing Surgery Due to Gastrointestinal Cancer: A Cross-Sectional Observational Study.
Karanikki E, Frountzas M, Lidoriki I, Kozadinos A, et al · · 2024 · cited 4× · PMID 39685936 · DOI 10.3390/jcm13237479
Verify or expand the search:
- PubMed search for NCT05795374
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastrointestinal Cancer
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
- NCT06936878 — BOLSTER: Learning New Skills to Thrive · NA · recruiting
- NCT06864169 — A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) · Phase 2 · active not recruiting
- NCT07056777 — Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastr · Phase 1, PHASE2 · recruiting
Other Maximos Frountzas trials
Trials by the same sponsor.
- NCT05548764 — Prevention Bundles for SSIs (PREBUSSI). · completed
- NCT05549076 — Hellenic Registry for cIAIs (HERCO-II) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05795374 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maximos Frountzas
- Last refreshed: 28 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05795374.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing